Chromogranin a is a reliable biomarker for gastroenteropancreatic neuroendocrine tumors in an Asian population of patients

Neuroendocrinology

Volumn 95, Issue 4, 2012, Pages 344-350

  Chou, Wen Chi ^a   Hung, Yu Shin ^a   Hsu, Jun Te ^a   Chen, Jen Shi ^a   Lu, Chang Hsien ^b   Hwang, Tsann Long ^a   Rau, Kun Ming ^b   Yeh, Kun Yun ^b   Chen, Tse Ching ^a   Sun, Chien Feng ^a  

^a CHANG GUNG UNIVERSITY COLLEGE OF MEDICINE   (Taiwan)

^b CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

Author keywords

Carbohydrate antigen 19 9; Carcinoembryonic antigen; Chromogranin A; Gastroenteropancreatic neuroendocrine tumors

Indexed keywords

CHROMOGRANIN A; PROTON PUMP INHIBITOR; SOMATOSTATIN DERIVATIVE;

ADULT; AGED; ARTICLE; ASIAN; CLINICAL ARTICLE; CLINICAL EXAMINATION; CONTROLLED STUDY; DISEASE ACTIVITY; FEMALE; GASTROINTESTINAL TUMOR; HISTOPATHOLOGY; HUMAN; MALE; NEUROENDOCRINE TUMOR; PANCREAS TUMOR; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; TREATMENT RESPONSE; TUMOR LOCALIZATION;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ASIAN CONTINENTAL ANCESTRY GROUP; CHROMOGRANIN A; FEMALE; GASTROINTESTINAL NEOPLASMS; HUMANS; MALE; MIDDLE AGED; NEUROENDOCRINE TUMORS; PANCREATIC NEOPLASMS; POPULATION; PREDICTIVE VALUE OF TESTS; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; TUMOR MARKERS, BIOLOGICAL; YOUNG ADULT;

EID: 84862772941     PISSN: 00283835     EISSN: 14230194     Source Type: Journal    
DOI: 10.1159/000333853     Document Type: Article

References (27)

1. Modlin IM, Lye KD, Kidd M: A 5-decade analysis of 13,715 carcinoid tumors. Cancer 2003;97: 934-959.
2. National Cancer Institute: US SEER Cancer Statistics Review, 1975-2004. http://seer.cancer.gov/csr/1975-2004.
3. Yao JC, Hassan M, Phan A, Dagohoy C, Leary C, Mares JE, Abdalla EK, Fleming JB, Vauthey JN, Rashid A, Evans DB: One hundred years after 'carcinoid': epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol 2008;26: 3063-3072.
4. Strosberg JR, Nasir A, Hodul P, Kvols L: Biology and treatment of metastatic gastrointestinal neuroendocrine tumors. Gastrointest Cancer Res 2008;2: 113-125.
5. Klöppel G, Perren A, Heitz PU: The gastroenteropancreatic neuroendocrine cell system and its tumors: the WHO classification. Ann NY Acad Sci 2004;1014: 13-27.
6. Bajetta E, Ferrari L, Martinetti A, et al: Chromogranin A, neuron specific enolase, carcinoembryonic antigen, and hydroxyindole acetic acid evaluation in patients with neuroendocrine tumors. Cancer 1999;86: 858-865.
7. Konecki DS, Benedum UM, Gerdes HH, et al: The primary structure of human chromogranin A and pancreastatin. J Biol Chem 1987;262: 17026-17030.
8. Kim T, Tao-Cheng JH, Eiden LE, et al: Chromogranin A, an 'on/off' switch controlling dense-core secretory granule biogenesis. Cell 2001;106: 499-509.
9. Taupenot L, Harper KL, O'Connor DT: The chromogranin-secretogranin family. N Engl J Med 2003;348: 1134-1149.
10. Tomassetti P, Migliori M, Simoni P, et al: Diagnostic value of plasma chromogranin A in neuroendocrine tumours. Eur J Gastroenterol Hepatol 2001;13: 55-58.
11. Campana D, Nori F, Piscitelli L, et al: Chromogranin A: is it a useful marker of neuroendocrine tumors? J Clin Oncol 2007;25:1967-1973.
12. Nobels F, Kwekkeboom D, Coopmans W, et al: Chromogranin A as serum marker for neuroendocrine neoplasia: comparison with neuron-specific enolase and the α-subunit of glycoprotein hormones. J Clin Endocrinol Metab 1997;82: 2622-2628.
13. Cimitan M, Buonadonna A, Cannizzaro R, et al: Somatostatin receptor scintigraphy versus chromogranin A assay in the management of patients with neuroendocrine tumors of different types: clinical role. Ann Oncol 2003;14: 1135-1141.
14. Namwongprom S, Wong FC, Tateishi U, et al: Correlation of chromogranin A levels and somatostatin receptor scintigraphy findings in the evaluation of metastases in carcinoid tumors. Ann Nucl Med 2008;22: 237-243.
15. Nehar D, Lombard-Bohas C, Olivieri S, et al: Interest of chromogranin A for diagnosis and follow-up of endocrine tumours. Clin Endocrinol (Oxf) 2004;60: 644-652.
16. Zatelli MC, Torta M, Leon A, et al: Chromogranin A as a marker of neuroendocrine neoplasia: an Italian Multicenter Study. Endocr Relat Cancer 2007;14: 473-482.
17. Welin S, Stridsberg M, Cunningham J, et al: Elevated plasma chromogranin A is the first indication of recurrence in radically operated midgut carcinoid tumors. Neuroendocrinology 2009;89: 302-307.
18. Bosman FT, Carneiro F, Hruban RH, et al: World Health Organization Classification of Tumours of the Digestive System. Lyon, IARC Press, 2010.
19. Yao JC, Lombard-Bohas C, Baudin E, et al: Daily oral everolimus activity in patients with metastatic pancreatic neuroendocrine tumors after failure of cytotoxic chemotherapy: a phase II trial. J Clin Oncol 2010;28:69-76.
20. Tomassetti P, Migliori M, Lalli S, et al: Epidemiology, clinical features and diagnosis of gastroenteropancreatic endocrine tumours. Ann Oncol 2001;12:S95-S99.
21. Janson ET, Holmberg L, Stridsberg M, et al: Carcinoid tumors: analysis of prognostic factors and survival in 301 patients from a referral center. Ann Oncol 1997;8: 685-690.
22. Nikou GC, Marinou K, Thomakos P, et al: Chromogranin a levels in diagnosis, treatment and follow-up of 42 patients with nonfunctioning pancreatic endocrine tumours. Pancreatology 2008;8: 510-519.
23. Modlin IM, Moss SF, Oberg K, et al: Gastrointestinal neuroendocrine (carcinoid) tumours: current diagnosis and management. Med J Aust 2010;193: 46-52.
24. Natori S, Huttner WB: Chromogranin B (secretogranin I) promotes sorting to the regulated secretory pathway of processing intermediates derived from a peptide hormone precursor. Proc Natl Acad Sci USA 1996;93: 4431-4436.
25. Stridsberg M, Eriksson B, Oberg K, et al: A comparison between three commercial kits for chromogranin A measurements. J Endocrinol 2003;177: 337-341.
26. Aardal S, Helle KB, Elsayed S, et al: Vasostatins, comprising the N-terminal domain of chromogranin A, suppress tension in isolated human blood vessel segments. J Neuroendocrinol 1993;5: 405-412.
27. Vezzosi D, Walter T, Laplanche A, et al: Chromogranin A measurement in metastatic well-differentiated gastroenteropancreatic neuroendocrine carcinoma: screening for false positives and a prospective follow-up study. Int J Biol Markers 2011;26: 94-101.